Capital Impact Advisors’s Lumos Pharma, Inc. Common Stock LUMO Stock Holding History

Capital Impact Advisors’s Portfolio LUMO Stock Details LUMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,603	Closed	-$263K	–	237
2016 Q1	$263K	Hold	1,603	–	–	0.13%	213
2015 Q4	$525K	Buy	1,603 +611	+62%	+$199K	0.25%	189
2015 Q3	$320K	Hold	992	–	–	0.16%	204
2015 Q2	$395K	Hold	992	–	–	0.18%	214
2015 Q1	$488K	Buy	992 +165	+20%	+$63.9K	0.22%	194
2014 Q4	$296K	Hold	827	–	–	0.14%	92
2014 Q3	$159	Hold	827	–	–	﹤0.01%	125
2014 Q2	$198K	Buy	+827	New	+$168K	0.15%	94

Other funds holding LUMO

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BIM

Bogle Investment Management Newton Lower Falls, Massachusetts $63M AUM 51.97% 1-Year Est. Return

Capital Impact Advisors's LUMO Position: Q2 2016 in Review

Capital Impact Advisors sold out of Lumos Pharma, Inc. Common Stock (LUMO) in Q2 2016, closing a stake of 1,603 shares — an estimated $263K sold.

Capital Impact Advisors first reported a position in LUMO in Q2 2014 and held it in 8 quarters. The position peaked at $525K in Q4 2015. 112 funds tracked by Wall St. Rank hold LUMO as of Q2 2016.

Capital Impact Advisors reported no remaining Lumos Pharma, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Capital Impact Advisors sold 1,603 Lumos Pharma, Inc. Common Stock shares in Q2 2016, an estimated $263K.
Capital Impact Advisors first reported a position in Lumos Pharma, Inc. Common Stock in Q2 2014 and held it in 8 quarters.
Capital Impact Advisors's Lumos Pharma, Inc. Common Stock position peaked at $525K in Q4 2015.
112 funds tracked by Wall St. Rank held Lumos Pharma, Inc. Common Stock as of Q2 2016.

Based on Capital Impact Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.